RIDGEFIELD, Conn., Jan. 12 /PRNewswire/ -- Boehringer Ingelheim today announced the appointment of Albert Ros as executive vice president of Sales and Marketing for the company's Prescription Medicines Business. In his new role, Ros will lead the U.S. sales and marketing strategy of Boehringer Ingelheim's core brands.
"We are pleased to have Albert in such an important leadership role," said J. Martin Carroll, President and Chief Executive Officer, Boehringer Ingelheim Corporation. "Albert is a valuable member of the Boehringer Ingelheim team and he possesses an impressive range of global sales and marketing experience."
Ros has been with Boehringer Ingelheim for 14 years and previously served as Head of Boehringer Ingelheim's Corporate Division for Marketing of Prescription Medicines. In this position, which he held since 2005, Ros led the development of four global products including Spiriva(R), Flomax(R), Mirapex(R) and Micardis(R). Previously, Ros served as the country manager for Boehringer Ingelheim Brazil and the business unit head of Boehringer Ingelheim Spain.
Ros earned a pharmacy degree from the
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For more information, please visit http://us.boehringer-ingelheim.com.
|SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved